Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
Hagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, Jorge E Cortes, Tim H Brümmendorf, Yun Su, Arlene L Reisman, Mark Shapiro, Jeff H Lipton, Hagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, Jorge E Cortes, Tim H Brümmendorf, Yun Su, Arlene L Reisman, Mark Shapiro, Jeff H Lipton
Abstract
Background: Health-related quality of life (HRQOL) in patients with chronic-phase chronic myeloid leukemia (CML) is important because of the requirement for long-term treatment. This study assessed HRQOL in bosutinib-treated patients with Philadelphia chromosome-positive CML and resistance or intolerance to 1 (chronic-phase second-line [CP2L]) or more (chronic-phase third-line [CP3L]) tyrosine kinase inhibitors who had 264 weeks or more of follow-up (ClinicalTrials.gov identifier NCT00261846).
Methods: Patient-reported HRQOL was assessed with the EuroQol 5-Dimensions Questionnaire (EQ-5D) and the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu).
Results: In total, 284 and 119 patients composed the CP2L and CP3L cohorts, respectively. At treatment completion, more than 50% of the patients in the CP2L and CP3L cohorts completed the EQ-5D and FACT-Leu assessments. The EQ-5D and EQ-5D visual analog scale scores were stable in both cohorts throughout treatment. The mean FACT-Leu scores were generally stable over time but were lower in magnitude in the CP3L cohort versus the CP2L cohort. The FACT-Leu scale scores of a subset of patients with chronic diarrhea (CP2L, n = 101; CP3L, n = 30) were similar to the scores of the larger cohorts. Minimally important differences (MIDs) from baseline for the FACT-Leu scale scores were observed for the following: emotional well-being (EWB), Functional Assessment of Cancer Therapy-General (FACT-G) Total, FACT-Leu Total, and Functional Assessment of Cancer Therapy Trial Outcome Index (FACT-TOI) in the CP2L cohort and FACT-Leu Total in the CP3L cohort. Among patients with chronic diarrhea, MIDs were observed for EWB, FACT-G Total, FACT-Leu Total, and FACT-TOI in the CP2L cohort and for EWB, FACT-G Total, and FACT-Leu Total in the CP3L cohort.
Conclusions: HRQOL was maintained with long-term bosutinib treatment for patients with CP2L and CP3L CML. Cancer 2018;124:587-95. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Keywords: bosutinib; chronic myeloid leukemia; patient-reported outcomes; quality of life; tyrosine kinase inhibitors.
© 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Figures
References
- O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low‐dose cytarabine for newly diagnosed chronic‐phase chronic myeloid leukemia. N Engl J Med. 2003;348:994‐1004.
- Druker BJ, Guilhot F, O'Brien SG, et al. Five‐year follow‐up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408‐2417.
- Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic‐phase chronic myeloid leukemia: 2‐year follow‐up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123‐1129.
- Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase: ENESTnd 3‐year follow‐up. Leukemia. 2012;26:2197‐2203.
- Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic‐phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303‐2309.
- Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200‐1206.
- Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR‐ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540‐3546.
- Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24‐month follow‐up results. Blood. 2011;117:1141‐1145.
- Shah NP, Guilhot F, Cortes JE, et al. Long‐term outcome with dasatinib after imatinib failure in chronic‐phase chronic myeloid leukemia: follow‐up of a phase 3 study. Blood. 2014;123:2317‐2324.
- Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381‐2388.
- Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401‐5411.
- Phillips KM, Pinilla‐Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097‐1103.
- Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual Life Outcomes. 2013;11:167.
- Bosulif [full prescribing information]. New York, NY: Pfizer Labs; 2014.
- Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI‐606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567‐4576.
- Lipton JH, Cortes JE, Khoury HJ, et al. Long‐term bosutinib in patients with chronic phase chronic myeloid leukemia after prior imatinib failure. Paper presented at: Annual Meeting of the American Society of Clinical Oncology; May 29 to June 2, 2015; Chicago, IL.
- Gambacorti‐Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24‐month follow‐up. Am J Hematol. 2014;89:732‐742.
- Brummendorf TH, Cortes JE, Khoury HJ, et al. Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016;172:97‐110.
- Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW. Health‐related quality of life of bosutinib (SKI‐606) in imatinib‐resistant or imatinib‐intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012;36:438‐442.
- Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D. Health‐related quality of life during bosutinib (SKI‐606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016;32:1325‐1334.
- van Reenan M, Oppe M. EQ‐5D‐3L User Guide (Version 5.1). Rotterdam, the Netherlands: EuroQol Group; 2015.
- Cella D, Jensen SE, Webster K, et al. Measuring health‐related quality of life in leukemia: the Functional Assessment of Cancer Therapy–Leukemia (FACT‐Leu) questionnaire. Value Health. 2012;15:1051‐1058.
- Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309‐1318.
- Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low‐dose cytarabine: results from the IRIS study. J Clin Oncol. 2003;21:2138‐2146.
- Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122:641‐647.
- Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2016;2016:170‐179.
Source: PubMed